查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1864800

内分泌药物市场按治疗领域、药物类别、给药途径、患者年龄层和通路－2025-2032年全球预测

Endocrinology Drugs Market by Therapy Area, Drug Class, Mode of Administration, Patient Age Group, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，内分泌药物市场规模将达到 1,097.8 亿美元，年复合成长率为 7.60%。

关键市场统计数据
基准年 2024 610.6亿美元
预计年份：2025年 654.3亿美元
预测年份 2032 1097.8亿美元
复合年增长率 (%) 7.60%

权威概述了治疗创新、监管变革和患者​​期望如何重塑内分泌学领域的药物策略和治疗路径。

由于许多疾病的慢性特征、生物製药和小分子药物的持续创新，以及患者对治疗便利性和疗效的期望不断变化，内分泌治疗在现代医疗保健中发挥核心作用。在临床和商业领域，相关人员越来越重视那些能够改善代谢控制、降低併发症发生率并透过改进製剂和给药系统来提高患者长期用药依从性的干预措施。因此，对于必须在临床疗效和实际应用挑战之间取得平衡的临床医生、商业领袖和政策顾问而言，整合治疗创新、监管发展和患者用药趋势的研究至关重要。

本执行摘要概述了当前形势，重点介绍了影响产品策略和患者照护路径的技术、监管和供应链发展。它阐述了糖尿病、甲状腺疾病、脑下垂体疾病和其他内分泌疾病的治疗进展，并强调了将药理学与数位健康、患者援助计划和新型分销模式相结合的重要性。读者将了解创新、支付方优先事项和全球贸易趋势如何相互交织，从而影响整个价值链的策略规划和营运执行。

生物製药、给药系统、数位疗法和法规结构的创新如何共同重塑内分泌治疗领域的竞争策略

内分泌学领域正经历变革性的转变，这主要得益于生物製药、胜肽工程和递送技术的进步，这些进步显着提高了疗效和患者用药的便利性。新型GLP-1受体促效剂和长效胰岛素类似物已确立了新的治疗标准，而製剂科学的进步则实现了减少给药频率和拓展给药途径。同时，数位健康平台和远端监测工具正与治疗方案相结合，以支持患者依从性、剂量调整和个人化治疗方案，这些也正在影响临床试验设计和上市后证据的产生。

在各个治疗领域，商业和法律规范也在不断发展，以适应加速核准、基于价值的合约和基于绩效的报销模式。这些趋势正在推动强有力的真实世界证据项目，并促进製造商、医疗服务提供者和支付者之间更紧密的合作。供应链韧性和生产灵活性也已成为战略重点，推动对区域生产能力和伙伴关係关係的投资，从而缩短前置作业时间并提高对需求波动的应对力。这些变化正在创造一个环境，​​在这个环境中，卓越的商业化和患者支持对于治疗方法的差异化至关重要。

2025年关税对医药生态系统内的供应链、筹资策略、生产决策和合约保护的实际影响

2025年推出的关税和贸易措施为整个医药价值链的定价、供应链设计和筹资策略带来了新的考量。关税相关成本的增加使原料药和成品药的进口变得更加复杂，促使製造商重新评估其成本结构，并制定应对关税、物流附加费和合规文件的方案。因此，采购和供应链负责人正优先考虑供应商多元化、尽可能选择近岸外包以及严格的库存管理，以降低边境相关成本波动带来的风险。

同时，监管机构和商业伙伴正积极应对不断变化的贸易环境，强调成本透明转嫁和合约保障，以抵御关税波动的影响。研发计画也反映了这些趋势，企业考虑在本地生产关键零件，优先采用模组化製造技术以实现高效规模化生产，并与供应商协商长期合约以稳定投入成本。这些务实的因应措施旨在确保患者获得医疗服务并维持治疗的连续性，同时发展能够适应高成本贸易环境的商业模式。

全面的细分观点可以清楚地展现跨治疗领域、药物类别、给药途径、患者人口统计特征和通路动态的临床重点、製剂形式和分销策略。

细分市场为理解治疗价值和商业性机会如何因临床适应症、分子类别、给药途径、患者群体和通路而异提供了一个切实可行的观点。对比肾上腺疾病、糖尿病、生长迟缓、骨质疏鬆症、脑下垂体疾病和甲状腺疾病等治疗领域与抑钙素肽、生长激素、胰岛素、口服降血糖药、口服降血糖药以及副甲状腺素及其类似物等药物类别，可以揭示研发复杂性、监管要求和患者依从性挑战方面的重要模式。不同的给药途径（吸入、注射、口服）进一步影响产品定位，而给药途径的便利性和稳定性等因素则影响临床应用和支付方的评估。

患者人口统计细分——成人、老年人和儿童——也影响临床试验设计、安全性监测和製剂优化的差异，因为不同族群的药物动力学和依从性行为存在差异。通路，包括医院、线上和零售药局，决定产品上市和长期可近性的商业性路径，影响从低温运输物流到病患咨询机会等方方面面。整合这些细分维度，可以揭示治疗创新可能快速扩散的领域、需要更多证据和递送创新的领域，以及患者支持在维持临床和商业性成功方面至关重要的领域。

区域法规结构、支付方趋势和基础设施因素如何推动美洲、欧洲、中东和非洲以及亚太地区的个人化医疗服务取得策略

区域特征对产品开发、监管规划和商业化的策略决策有显着影响。在美洲，成熟的支付方体系和完善的专科诊疗路径有利于差异化治疗方法的快速推广，但报销压力和价格敏感性要求提供强有力的卫生经济学证据和结构化的患者支持项目。这种环境有利于那些能展现明确临床效益、改善病患预后，同时又能为医疗保健系统带来显着成本节约的产品。

在欧洲、中东和非洲地区，复杂的监管环境和多样化的报销机制要求企业制定个人化的打入市场策略和弹性价格设定方式。由于各地区基础设施和准入管道存在差异，製造商需要设计差异化的分销和准入方案，以同时满足公共医疗采购和私人专科管道的需求。在亚太地区，新技术快速普及和对本土製造的日益重视是显着的趋势。不同的监管路径和市场成熟度为当地企业、共同开发契约以及结合全球专业知识和本地执行能力的混合商业化模式创造了机会。

领先製药公司采取的策略行动和业务投资优先考虑产品线差异化、生产灵活性和一体化的患者准入解决方案。

产业相关人员正在製定策略应对措施，以应对治疗和商业方面的压力，这些措施强调专业化、营运韧性和伙伴关係。主要企业正优先考虑透过内部创新和外部联盟来实现产品线差异化，这些联盟能够提供互补能力，例如先进的製剂科学、生物製剂工程和数位化依从性平台。策略授权和共同开发契约可以加快产品上市速度，同时分散开发风险，并有助于获得当地监管的专业知识。

在营运方面，各公司正投资于灵活的生产平台、先进的低温运输和品质保证流程，以减少供应中断并支援国际分销。商业策略正在加速采用按绩效付费合约和整合式患者服务，以确保处方笺被纳入处方集并促进长期用药依从性。同时，中型市场和专科公司正透过提供高度个人化的患者支援和临床医生教育计画来开拓市场，这些计画与其治疗方案相辅相成，并强化了品牌差异化。总而言之，这些倡议反映了整个产业向整合式解决方案的转变，这种解决方案将临床价值与实际可及性相结合。

产业领导者应重点关注以下切实可行的策略事项：加强供应链韧性、强化与支付方的伙伴关係以及将数位化能力融入医疗服务。

产业领导者应采取多管齐下的策略，在科学创新、实际应用和业务永续营运之间取得平衡。首先，应优先考虑供应链多元化和短期紧急时应对计画，以降低贸易相关成本衝击的影响。应就关键原料药(API) 建立多源采购协议，并考虑建立区域生产伙伴关係，以减少对单一地区的依赖。同时，应加快对製剂和给药方式创新的投资，以提高患者依从性、减轻给药负担，并扩大成人、老年人和儿童患者的覆盖范围。

第二，透过早期卫生经济学建模和结果资料收集，加强与支付方的合作，以支持基于价值的合约。制定真实世界证据项目和患者报告结果 (PRO)倡议，以证明长期疗效并为定价讨论提供基础。第三，建立伙伴关係，将数位健康能力融入医疗服务，实现远端监测、依从性支援和个人化给药方案。最后，将监管前瞻性纳入研发计划，在适当情况下利用加速核准途径，并设计符合上市后证据要求的核准方案。透过共同实施这些倡议，各机构将能够更好地提供差异化的临床价值，同时有效管理商业性和营运风险。

严谨的多方面研究途径，结合专家访谈、监管审查、临床证据综合和分段分析，验证了检验并指出了其局限性。

本研究整合了透过与临床医生、支付方、供应链经理和行业高管的专家访谈收集的关键发现，并结合对监管指导文件、临床文献和公共公告的全面审查。调查方法方法强调三角验证，将从相关人员对话中获得的见解与监管记录、已发表的临床试验结果和商业资讯披露进行交叉比对，以检验结论反映出趋同的证据基础。研究采用细分映射法，将治疗适应症、药物类别、给药途径、年龄层和分销管道与临床和商业性属性相匹配。

品管包括与领域专家进行交叉检验、反覆进行主题提炼，以及针对供应链和政策相关解读的敏感度检查。局限性包括贸易措施的动态性以及政策实施与可观察到的商业性影响之间的滞后性。该分析恰当地区分了已记录的变化和可能出现的近期应对措施。资讯来源选择和调查方法的透明度使读者能够评估研究结果对其特定组织环境的适用性，并可要求针对特定领域或地区进行客製化的深度分析。

综合分析研究结果，强调整合证据产生、加强供应链韧性以及相关人员合作对于实现治疗进展的重要性。

治疗方法、支付方期望的转变以及贸易相关的成本压力交织在一起，需要研发、生产和商业部门协同应对。胜肽工程、生物製药和递送系统的治疗进展为改善患者疗效创造了新的机会，但要充分发挥这些潜力，需要製定切实可行的策略，以确保治疗的可负担性、可及性和依从性。那些将实证医学研究与以病人为中心的服务模式和稳健的供应链结合的机构，将更有能力把临床创新转化为持久的健康效益。

展望未来，製造商、医疗服务提供者、支付方和监管机构之间的持续合作对于应对不断变化的报销模式和地缘政治对贸易的影响至关重要。对区域製造、数位健康整合和真实世界证据能力的策略性投资将带来可持续的竞争优势。最终，成功取决于将卓越的科学技术与营运适应能力以及各相关人员之间的合作相结合，以确保治疗方面的进步能够转化为患者照护方面可衡量的改善。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • GLP-1受体促效剂的应用范围已从糖尿病管理扩展到肥胖症治疗；口服甲状腺刺激素受体调变器获得监管部门核准，为甲状腺机能低下症患者提供了一种非侵入性治疗选择；数位健康平台与智慧胰岛素笔的整合
  • 口服甲状腺刺激素受体调变器的核准为甲状腺机能低下症患者提供了一种非侵入性治疗选择。
  • 数位健康平台与智慧胰岛素笔的整合可提高糖尿病患者的治疗顺从性和血糖控制效果。
  • 针对罕见内分泌疾病的个人化胜肽疗法正透过精准医疗倡议广受关注。
  • 针对肾上腺功能不全的新兴联合治疗既满足了皮质醇替代的需求，也满足了免疫调节的需求。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 内分泌药物市场（依治疗领域划分）

  • 肾上腺疾病
  • 糖尿病
  • 生长迟缓
  • 骨质疏鬆症
  • 脑下垂体疾病
  • 甲状腺疾病

第九章 内分泌药物市场（依药物类别划分）

  • 抑钙素肽
  • 生长激素
  • 胰岛素
  • 口服降血糖药
  • 口服降血糖药物
  • 副甲状腺素及其类似物

第十章 内分泌药物市场依给药途径划分

  • 吸入剂
  • 注射
  • 口服

第十一章 依患者年龄层分類的内分泌药物市场

  • 成人版
  • 老年人
  • 孩子们

第十二章 内分泌药物市场（依分销管道划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十三章 内分泌药物市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 内分泌药物市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国内分泌药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Abbott Laboratories
    • AbbVie Inc.
    • Ascendis Pharma A/S
    • AstraZeneca PLC
    • Bayer AG
    • Biocon Limited
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • CHIESI Farmaceutici SpA
    • Eli Lilly and Company
    • Endo, Inc.
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline PLC
    • Hanmi Pharm Co., Ltd.
    • Ipsen Pharma
    • Johnson & Johnson Services, Inc.
    • MacroGenics, Inc.
    • MannKind Corporation
    • Merck & Co., Inc.
    • Novartis AG
    • Novo Nordisk A/S
    • Oramed Pharmaceuticals Inc.
    • Pfizer Inc.
    • Precigen, Inc.
    • Sanofi SA
    • Shenzhen Microchip Biotechnology Co., Ltd.
    • Sun Pharmaceutical Industries Limited
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-D1342F184FD3

The Endocrinology Drugs Market is projected to grow by USD 109.78 billion at a CAGR of 7.60% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 61.06 billion
Estimated Year [2025] USD 65.43 billion
Forecast Year [2032] USD 109.78 billion
CAGR (%) 7.60%

An authoritative overview of how therapeutic innovation, regulatory shifts, and patient expectations are reshaping endocrinology drug strategies and care pathways

Endocrinology therapeutics occupy a central role in modern healthcare due to the chronic nature of many conditions, the ongoing innovation in biologics and small molecules, and evolving patient expectations for convenience and outcomes. Across clinical and commercial settings, stakeholders increasingly prioritize interventions that improve metabolic control, reduce complication rates, and support long-term adherence through improved formulations and delivery systems. Consequently, research that synthesizes therapeutic innovation, regulatory dynamics, and patient access trends is essential for clinicians, commercial leaders, and policy advisors who must balance clinical efficacy with real-world implementation challenges.

This executive summary frames the contemporary landscape by highlighting technological, regulatory, and supply chain developments that shape product strategy and patient care pathways. It contextualizes therapeutic progress in diabetes, thyroid, pituitary, and other endocrine conditions while emphasizing the importance of integrated approaches that combine pharmacology with digital health, patient support programs, and novel distribution models. Readers are guided to consider how innovation, payer priorities, and global trade dynamics converge to influence strategic planning and operational execution across the value chain.

How innovations in biologics, delivery systems, digital therapeutics, and regulatory frameworks are jointly redefining competitive strategies across endocrinology treatments

The endocrinology landscape is undergoing transformative shifts driven by advances in biologics, peptide engineering, and delivery technologies that enhance both efficacy and patient convenience. Novel GLP-1 receptor agonists and long-acting insulin analogs have catalyzed new standards of care, while improvements in formulation science enable less frequent dosing and alternative administration routes. Concurrently, digital health platforms and remote monitoring tools are integrating with therapeutic regimens to support adherence, titration, and personalized care plans, which in turn influence clinical trial design and post-market evidence generation.

Beyond therapeutics, commercial and regulatory frameworks are evolving to accommodate accelerated approvals, value-based contracting, and outcomes-based reimbursement. These trends incentivize robust real-world evidence programs and closer alignment between manufacturers, providers, and payers. Supply chain resilience and manufacturing flexibility have also become strategic priorities, prompting investments in regional production capabilities and partnerships that reduce lead times and improve responsiveness to demand fluctuations. Taken together, these shifts are creating an environment where therapeutic differentiation must be matched by excellence in commercialization and patient support.

Realistic implications of 2025 tariff measures on supply chains, sourcing strategies, manufacturing decisions, and contractual protections within the pharmaceutical ecosystem

The introduction of tariffs and trade measures in 2025 has introduced new considerations for pricing, supply chain design, and sourcing strategies across the pharmaceutical value chain. Tariff-related costs increase the complexity of importing active pharmaceutical ingredients and finished products, thereby prompting manufacturers to revisit cost structures and engage in scenario planning for customs duties, logistics surcharges, and compliance-related documentation. Consequently, procurement teams and supply chain executives have prioritized supplier diversification, nearshoring where feasible, and tighter inventory management to mitigate exposure to border-related cost volatility.

In parallel, regulatory authorities and commercial partners are responding to the changed trade environment by emphasizing transparency in cost pass-through and contractual protections that address tariff fluctuations. Research and development planning also reflects these dynamics; companies are exploring localized manufacturing for critical components, prioritizing modular production technologies that scale efficiently, and negotiating long-term agreements with suppliers to stabilize input costs. These pragmatic responses seek to preserve patient access and maintain continuity of care while adapting commercial models to a higher-cost trading environment.

Integrated segmentation perspectives that reveal clinical, formulation, and distribution priorities across therapy areas, drug classes, administration modes, demographics, and channel dynamics

Segmentation provides a practical lens for understanding how therapeutic value and commercial opportunity vary across clinical indications, molecule classes, modes of delivery, patient demographics, and distribution pathways. When therapy areas such as Adrenal Disorders, Diabetes, Growth Disorders, Osteoporosis, Pituitary Disorders, and Thyroid Disorders are juxtaposed with drug classes that include Calcitonin Peptides, Growth Hormone, Insulin, Oral Antidiabetics, Oral Hypoglycemics, and Parathyroid Hormones & Analogs, important patterns emerge in terms of development complexity, regulatory requirements, and patient adherence challenges. Mode of administration distinctions-Inhalable, Injectable, and Oral-further shape product positioning, with route-specific convenience and stability considerations influencing clinical adoption and payer evaluations.

Patient age group segmentation between Adult, Geriatric, and Pediatric populations also drives differentiated clinical trial design, safety monitoring, and formulation optimization, given varied pharmacokinetics and adherence behaviors across cohorts. Distribution channels that encompass Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies determine the commercial pathway for product launch and long-term access, affecting everything from cold chain logistics to patient counseling opportunities. Integrating these segmentation dimensions illuminates where therapeutic innovations are likely to achieve rapid uptake, where additional evidence or delivery innovation is necessary, and where patient support will be a decisive factor in sustained clinical and commercial success.

How regional regulatory frameworks, payer dynamics, and infrastructure considerations drive tailored access strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics materially influence the strategic calculus for product development, regulatory planning, and commercialization. In the Americas, a mature payer ecosystem and established specialty care pathways support rapid adoption of differentiated therapies, although reimbursement pressure and price sensitivity require robust health economic evidence and well-structured patient support programs. This environment favors products that demonstrate clear clinical benefit and improved patient outcomes while delivering demonstrable cost offsets for healthcare systems.

In Europe, Middle East & Africa, regulatory complexity and heterogeneous reimbursement mechanisms necessitate tailored market entry strategies and flexible pricing approaches. Regional variation in infrastructure and access pathways means that manufacturers must design differentiated distribution and access programs that accommodate public healthcare procurement as well as private specialty channels. In the Asia-Pacific region, rapid adoption of new technologies and a growing emphasis on domestic manufacturing are notable trends. Diverse regulatory pathways and varying degrees of market maturity create opportunities for partnerships with local firms, co-development arrangements, and hybrid commercialization models that balance global expertise with local execution capabilities.

Strategic behaviors and operational investments by leading pharmaceutical companies that prioritize pipeline differentiation, manufacturing flexibility, and integrated patient access solutions

Industry actors are responding to therapeutic and commercial pressures with strategic moves that emphasize specialization, operational resilience, and partnership. Leading companies are prioritizing pipeline differentiation through both internal innovation and external alliances that deliver complementary capabilities, such as advanced formulation science, biologics engineering, or digital adherence platforms. Strategic licensing and co-development arrangements help accelerate time-to-market while distributing development risk and enabling access to local regulatory expertise.

Operationally, firms are investing in flexible manufacturing platforms, cold chain sophistication, and quality assurance processes that reduce supply disruptions and support international distribution. Commercial strategies increasingly incorporate outcomes-oriented contracting and integrated patient services to secure formulary positions and nurture long-term adherence. In parallel, mid-sized and specialty companies are carving out niches by delivering high-touch patient support and clinician education programs that complement therapeutic profiles and strengthen brand differentiation. Collectively, these behaviors reflect a sector-wide pivot toward integrated solutions that pair clinical value with pragmatic access mechanisms.

Practical strategic priorities for industry leaders to enhance supply chain resilience, strengthen payer partnerships, and integrate digital capabilities into therapeutic offerings

Industry leaders should adopt a multifaceted strategy that aligns scientific innovation with pragmatic access and operational resilience. First, prioritize supply chain diversification and near-term contingency planning to reduce exposure to trade-related cost shocks. Establish multi-sourcing agreements for critical APIs and consider regional production partnerships that lower dependency on single geographies. Simultaneously, accelerate investments in formulation and delivery innovations that improve adherence, reduce administration burden, and expand the addressable patient population across adult, geriatric, and pediatric cohorts.

Second, strengthen payer engagement through early health economic modelling and outcomes data collection to support value-based contracting. Develop real-world evidence programs and patient-reported outcomes initiatives that substantiate long-term benefits and inform pricing discussions. Third, cultivate partnerships that bring digital health capabilities into therapeutic offerings, enabling remote monitoring, adherence support, and personalized dosing regimens. Finally, embed regulatory foresight into R&D planning to leverage expedited pathways where appropriate and to design registrational programs that reflect post-market evidence requirements. Collectively, these actions will position organizations to deliver differentiated clinical value while managing commercial and operational risk.

A rigorous, multi-method research approach combining expert interviews, regulatory review, clinical evidence synthesis, and segmented analysis to validate insights and identify limitations

This research synthesizes primary insights gathered through expert interviews with clinicians, payers, supply chain managers, and industry executives alongside a thorough review of regulatory guidance documents, clinical literature, and public policy announcements. The methodological approach emphasizes triangulation: findings from stakeholder conversations were validated against regulatory records, published clinical trial results, and operational disclosures to ensure that conclusions reflect a convergent evidence base. Segmentation mapping was applied to align therapeutic indications, drug classes, modes of administration, age groups, and distribution channels with clinical and commercial attributes.

Quality control included cross-validation by domain experts, iterative refinement of themes, and sensitivity checks on supply chain and policy-related interpretations. Limitations stem from the evolving nature of trade measures and the lag between policy implementation and observable commercial impacts; where appropriate, the analysis distinguishes between documented changes and plausible near-term responses. Transparency about sources and methodological choices enables readers to assess the applicability of insights to their specific organizational contexts and to request bespoke deep dives focused on particular segments or geographies.

Consolidating insights to emphasize the imperative for integrated evidence generation, supply chain resilience, and stakeholder collaboration to realize therapeutic advances

The confluence of therapeutic innovation, changing payer expectations, and trade-related cost pressures requires a coordinated response across R&D, manufacturing, and commercial functions. Therapeutic advances in peptide engineering, biologics, and delivery systems are creating new opportunities for improved patient outcomes, yet realizing that potential depends on pragmatic strategies that ensure affordability, access, and adherence. Organizations that integrate evidence generation with patient-centric service models and resilient supply chains will be best positioned to convert clinical innovation into sustained health impact.

Looking ahead, continued collaboration among manufacturers, providers, payers, and regulators will be essential to navigate evolving reimbursement paradigms and to respond to geopolitical influences on trade. Strategic investments in regional manufacturing, digital health integration, and real-world evidence capabilities will provide durable advantages. Ultimately, success will hinge on the ability to combine scientific excellence with operational adaptability and stakeholder alignment so that therapeutic advances translate into measurable improvements in patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growth of GLP-1 receptor agonists for obesity management beyond diabetes management
  • 5.2. Introduction of insulin biosimilars fueling price competition and market access challenges in emerging economies
  • 5.3. Regulatory approval of oral thyrotropin receptor modulators offering noninvasive treatment options for hypothyroidism patients
  • 5.4. Integration of digital health platforms with smart insulin pens improving adherence and glycemic control outcomes in diabetics
  • 5.5. Personalized peptide therapies targeting rare endocrine disorders gaining traction through precision medicine initiatives
  • 5.6. Emerging combination therapies for adrenal insufficiency addressing both cortisol replacement and immune modulation requirements

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Endocrinology Drugs Market, by Therapy Area

  • 8.1. Adrenal Disorders
  • 8.2. Diabetes
  • 8.3. Growth Disorders
  • 8.4. Osteoporosis
  • 8.5. Pituitary Disorders
  • 8.6. Thyroid Disorders

9. Endocrinology Drugs Market, by Drug Class

  • 9.1. Calcitonin Peptides
  • 9.2. Growth Hormone
  • 9.3. Insulin
  • 9.4. Oral Antidiabetics
  • 9.5. Oral Hypoglycemics
  • 9.6. Parathyroid Hormones & Analogs

10. Endocrinology Drugs Market, by Mode of Administration

  • 10.1. Inhalable
  • 10.2. Injectable
  • 10.3. Oral

11. Endocrinology Drugs Market, by Patient Age Group

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Endocrinology Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Endocrinology Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Endocrinology Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Endocrinology Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott Laboratories
    • 16.3.2. AbbVie Inc.
    • 16.3.3. Ascendis Pharma A/S
    • 16.3.4. AstraZeneca PLC
    • 16.3.5. Bayer AG
    • 16.3.6. Biocon Limited
    • 16.3.7. Boehringer Ingelheim International GmbH
    • 16.3.8. Bristol-Myers Squibb Company
    • 16.3.9. CHIESI Farmaceutici S.p.A.
    • 16.3.10. Eli Lilly and Company
    • 16.3.11. Endo, Inc.
    • 16.3.12. F. Hoffmann-La Roche Ltd.
    • 16.3.13. GlaxoSmithKline PLC
    • 16.3.14. Hanmi Pharm Co., Ltd.
    • 16.3.15. Ipsen Pharma
    • 16.3.16. Johnson & Johnson Services, Inc.
    • 16.3.17. MacroGenics, Inc.
    • 16.3.18. MannKind Corporation
    • 16.3.19. Merck & Co., Inc.
    • 16.3.20. Novartis AG
    • 16.3.21. Novo Nordisk A/S
    • 16.3.22. Oramed Pharmaceuticals Inc.
    • 16.3.23. Pfizer Inc.
    • 16.3.24. Precigen, Inc.
    • 16.3.25. Sanofi S.A
    • 16.3.26. Shenzhen Microchip Biotechnology Co., Ltd.
    • 16.3.27. Sun Pharmaceutical Industries Limited
    • 16.3.28. Takeda Pharmaceutical Company Limited
    • 16.3.29. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ENDOCRINOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ENDOCRINOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ENDOCRINOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADRENAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADRENAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADRENAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADRENAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADRENAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADRENAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY OSTEOPOROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY OSTEOPOROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY OSTEOPOROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY OSTEOPOROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY OSTEOPOROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY OSTEOPOROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PITUITARY DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PITUITARY DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PITUITARY DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PITUITARY DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PITUITARY DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PITUITARY DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THYROID DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THYROID DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THYROID DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THYROID DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY CALCITONIN PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY CALCITONIN PEPTIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY CALCITONIN PEPTIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY CALCITONIN PEPTIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY CALCITONIN PEPTIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY CALCITONIN PEPTIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH HORMONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH HORMONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH HORMONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH HORMONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH HORMONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH HORMONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INSULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INSULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INSULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INSULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL HYPOGLYCEMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL HYPOGLYCEMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL HYPOGLYCEMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL HYPOGLYCEMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL HYPOGLYCEMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL HYPOGLYCEMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PARATHYROID HORMONES & ANALOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PARATHYROID HORMONES & ANALOGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PARATHYROID HORMONES & ANALOGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PARATHYROID HORMONES & ANALOGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PARATHYROID HORMONES & ANALOGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PARATHYROID HORMONES & ANALOGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INHALABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INHALABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INHALABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INHALABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INHALABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INHALABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 244. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 245. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 246. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 253. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 256. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 257. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 258. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 259. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 280. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 281. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 282. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 283. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 288. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 289. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 292. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 293. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 294. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 295. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 296. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 297. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 298. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 299. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 300. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 301. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 304. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 305. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 306. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 307. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 308. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 309. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 310. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 311. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 316. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 317. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 318. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 319. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 320. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 321. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 322. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 323. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 324. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 325. CANADA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 326. CANADA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 327. CANADA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 328. CANADA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 329. CANADA ENDOCRINOLOGY DRUG